CBIO Crescent Biopharma, Inc.

NASDAQ
$17.14

Crescent Biopharma, Inc. (CBIO) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.71 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +16.9% since its last earnings release on July 30, 2026.

Crescent Biopharma Beat Consensus Estimates
Thursday, July 30, 2026 · 7:35 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($0.71)
Rev est $1.02M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.04

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Crescent Biopharma, Inc.

Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. Crescent Biopharma, formerly known as GlycoMimetics Inc., is based in ROCKVILLE, Md.

Sector

Healthcare

Industry

Biotechnology